Fazio S, Biondi B, Carella C, Sabatini D, Cittadini A, Panza N, Lombardi G, Saccà L
Department of Internal Medicine, University Federico II, Napoli, Italy.
J Clin Endocrinol Metab. 1995 Jul;80(7):2222-6. doi: 10.1210/jcem.80.7.7608283.
Thyroid-stimulating hormone (TSH) suppressive therapy with levothyroxine (L-T4) may cause adverse cardiac effects such as rhythm disturbances and ventricular hypertrophy. The latter is a predisposing condition to diastolic dysfunction. Thus, this study was designed to assess the effect of long-term TSH suppressive therapy on cardiac diastolic function. Because beta-blockade is known to reduce ventricular hypertrophy in patients on L-T4 therapy, we also tried to determine whether the addition of a beta-blocker to L-T4 improved diastolic function. Twenty-five patients (21 female and 4 male; mean age 41 +/- 10 yr) on TSH suppressive therapy for 3-9 yr (9 for differentiated carcinoma and 16 for nontoxic goiter) and 20 control subjects were studied. A subgroup of 10 patients, selected for the presence of symptoms and signs of adrenergic overactivity, was treated for 4 months with the beta-blocker bisoprolol (4.25 +/- 1.2 mg/day), and their maintaining L-T4 therapy was unchanged. In the patient group, left ventricular mass was significantly increased (P < 0.001), isovolumic relaxation time was prolonged (P < 0.001), and early diastolic filling velocity was markedly reduced (P < 0.001), whereas late diastolic filling was increased (P < 0.005). Consequently, the early-to-late diastolic flow velocity ratio was markedly decreased (P < 0.001). These alterations were more pronounced in the subgroup of patients with evidence of adrenergic overactivity. In these patients, beta-blockade induced a significant regression of cardiac hypertrophy and improved diastolic dysfunction. In particular, isovolumic relaxation time decreased (P < 0.01) and the early-to-late flow velocity ratio increased significantly (P < 0.01). Both indices reached values after beta-blockade that were no longer different from those of asymptomatic patients. It is concluded that long-term L-T4 therapy increases myocardial mass and causes relevant diastolic dysfunction, particularly in those patients with evidence of mild hyperthyroidism and adrenergic overactivity. Both myocardial hypertrophy and diastolic dysfunction are significantly improved by adrenergic beta-blockade.
用左甲状腺素(L-T4)进行促甲状腺激素(TSH)抑制治疗可能会引起不良心脏效应,如心律失常和心室肥厚。后者是舒张功能障碍的一个易感因素。因此,本研究旨在评估长期TSH抑制治疗对心脏舒张功能的影响。由于已知β受体阻滞剂可减轻接受L-T4治疗患者的心室肥厚,我们还试图确定在L-T4治疗中加用β受体阻滞剂是否能改善舒张功能。对25例接受TSH抑制治疗3至9年的患者(21例女性和4例男性;平均年龄41±10岁,其中9例为分化型癌,16例为非毒性甲状腺肿)和20例对照者进行了研究。选择10例有肾上腺素能活性亢进症状和体征的患者亚组,用β受体阻滞剂比索洛尔(4.25±1.2mg/天)治疗4个月,其维持的L-T4治疗不变。在患者组中,左心室质量显著增加(P<0.001),等容舒张时间延长(P<0.001),舒张早期充盈速度显著降低(P<0.001),而舒张晚期充盈增加(P<0.005)。因此,舒张早期与晚期血流速度比值显著降低(P<0.001)。这些改变在有肾上腺素能活性亢进证据的患者亚组中更为明显。在这些患者中,β受体阻滞剂治疗使心脏肥厚显著消退,并改善了舒张功能障碍。特别是,等容舒张时间缩短(P<0.01),舒张早期与晚期血流速度比值显著增加(P<0.01)。β受体阻滞剂治疗后这两个指标的值与无症状患者的值不再有差异。结论是,长期L-T4治疗会增加心肌质量并导致相关的舒张功能障碍,特别是在那些有轻度甲状腺功能亢进和肾上腺素能活性亢进证据的患者中。肾上腺素能β受体阻滞剂可显著改善心肌肥厚和舒张功能障碍。